You searched for "Lucentis"

272 results found

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Uveitis in the elderly

This study from Turkey evaluated the causes and clinical characteristics of uveitis in elderly patients. Data from 90 eyes of 68 patients aged 60 years and older were reviewed. Anterior uveitis was present in 75% (33% of these had keratouveitis),...

A paradigm shift in the way we approach cataract surgery

Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...

Sarcoid uveitis and its systemic associations

This retrospective cross-sectional study examined systemic associations of sarcoid uveitis and association with uveitis clinical phenotype and ethnicity. Three hundred and sixty-two subjects with either definite or presumed sarcoid uveitis were identified and included in the study. Any subject with...

Uveitis in HIV infected persons

Before the advent of highly active antiretroviral therapy (HAART), uveitis, in particular cytomegalovirus (CMV) retinitis, was the most common cause of visual loss in patients with AIDS. HAART has altered the cause of ocular disease in HIV infected individuals by...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Feb/Mar 2015 Quiz 1

A 79-year-old male presented to the ophthalmic emergency department with a three week history of left eye pain. He also reported visual deterioration in the left eye over the same period. He suffered from degenerative myopia, with his spectacle prescription...

Systemic anti-inflammatory versus fluocinolone acetonide intraocular implant

In the Multicenter Uveitis Steroid Treatment (MUST) trial, 255 patients with intermediate uveitis, posterior uveitis or panuveitis were randomised to either fluocinolone acetonide intraocular implant or systemic corticosteroid therapy which was supplemented with immunosuppression if required. Patients were followed up...

Using a driving simulator to explore the effect of visual field loss from optic disc drusen

The purpose of this study was to compare driving simulator performance of participants with visual field loss (VFL) from optic disc drusen (ODD) with a normally sighted control group and a group of individuals with glaucoma. Data on performance and...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...